Lannett Co Inc (NYSE:LCI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, July 18th. The brokerage presently has a $25.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 52.44% from the company’s current price.
According to Zacks, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies. “
A number of other research firms have also recently weighed in on LCI. BMO Capital Markets initiated coverage on shares of Lannett Co in a research note on Monday, May 1st. They set a “market perform” rating and a $29.00 target price on the stock. ValuEngine cut shares of Lannett Co from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Roth Capital set a $27.00 target price on shares of Lannett Co and gave the stock a “buy” rating in a research note on Tuesday, May 2nd. Robert W. Baird reiterated an “outperform” rating and set a $18.00 price target on shares of Lannett Co in a report on Wednesday, May 3rd. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $23.00 price target (up previously from $22.00) on shares of Lannett Co in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. Lannett Co has an average rating of “Hold” and a consensus target price of $27.50.
Lannett Co (LCI) opened at 16.40 on Tuesday. Lannett Co has a 12-month low of $15.75 and a 12-month high of $39.99. The stock has a 50 day moving average price of $20.02 and a 200-day moving average price of $21.30. The stock’s market capitalization is $610.57 million.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/08/12/lannett-co-inc-nyselci-rating-increased-to-buy-at-zacks-investment-research-updated-updated-updated.html.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Lannett Co by 52,610.9% in the first quarter. BlackRock Inc. now owns 3,903,766 shares of the company’s stock valued at $87,250,000 after buying an additional 3,896,360 shares during the last quarter. Snow Capital Management LP raised its position in Lannett Co by 22.5% in the first quarter. Snow Capital Management LP now owns 3,093,435 shares of the company’s stock valued at $69,138,000 after buying an additional 567,800 shares during the last quarter. Vanguard Group Inc. raised its position in Lannett Co by 6.2% in the second quarter. Vanguard Group Inc. now owns 2,901,885 shares of the company’s stock valued at $59,198,000 after buying an additional 168,454 shares during the last quarter. LSV Asset Management raised its position in Lannett Co by 13.6% in the first quarter. LSV Asset Management now owns 1,691,935 shares of the company’s stock valued at $37,814,000 after buying an additional 202,878 shares during the last quarter. Finally, Morgan Stanley raised its position in Lannett Co by 592.6% in the first quarter. Morgan Stanley now owns 1,339,367 shares of the company’s stock valued at $29,935,000 after buying an additional 1,145,987 shares during the last quarter. Institutional investors and hedge funds own 95.14% of the company’s stock.
About Lannett Co
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Lannett Co Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lannett Co Inc and related companies.